Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia

Adult acute lymphoblastic leukemia (ALL) has a poor overall survival compared with pediatric ALL where cure rates are observed in more than 90% of patients. The recent development of novel monoclonal antibodies targeting CD20, CD19, and CD22 has changed the long-term outcome of this disease, both in...

Full description

Bibliographic Details
Main Authors: Veronica A. Guerra, Elias J. Jabbour, Farhad Ravandi, Hagop Kantarjian, Nicholas J. Short
Format: Article
Language:English
Published: SAGE Publishing 2019-05-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/2040620719849496

Similar Items